Eupraxia Pharmaceuticals Inc. (EPRX.TO)
CAD 4.59
(-2.34%)
CAD 4.59
(-2.34%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -209.91 Thousand CAD | -8.61% |
| 2022 | -193.27 Thousand CAD | -73.29% |
| 2021 | -111.52 Thousand CAD | 4.52% |
| 2020 | -116.8 Thousand CAD | 42.16% |
| 2019 | -201.93 Thousand CAD | -60.49% |
| 2018 | -125.82 Thousand CAD | -47.38% |
| 2017 | -85.37 Thousand CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -57.5 Thousand CAD | -13.97% |
| 2024 Q1 | -50.46 Thousand CAD | -103.39% |
| 2023 Q3 | -49.9 Thousand CAD | -1.46% |
| 2023 FY | -209.91 Thousand CAD | -8.61% |
| 2023 Q4 | 1.48 Million CAD | 3084.49% |
| 2023 Q2 | -49.18 Thousand CAD | -1.17% |
| 2023 Q1 | -48.61 Thousand CAD | 11.8% |
| 2022 Q2 | -48.89 Thousand CAD | -24.22% |
| 2022 Q4 | -55.12 Thousand CAD | -10.5% |
| 2022 FY | -193.27 Thousand CAD | -73.29% |
| 2022 Q1 | -39.36 Thousand CAD | 4.95% |
| 2022 Q3 | -49.88 Thousand CAD | -2.02% |
| 2021 Q2 | -20.31 Thousand CAD | -0.37% |
| 2021 Q4 | -41.41 Thousand CAD | -40.07% |
| 2021 Q1 | -20.23 Thousand CAD | 0.0% |
| 2021 FY | -111.52 Thousand CAD | 4.52% |
| 2021 Q3 | -29.56 Thousand CAD | -45.55% |
| 2020 Q2 | - CAD | 0.0% |
| 2020 FY | -116.8 Thousand CAD | 42.16% |
| 2020 Q4 | - CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| 2020 Q1 | - CAD | 0.0% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 FY | -201.93 Thousand CAD | -60.49% |
| 2019 Q4 | - CAD | 0.0% |
| 2018 FY | -125.82 Thousand CAD | -47.38% |
| 2017 FY | -85.37 Thousand CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Appili Therapeutics Inc. | 813.74 Thousand CAD | 125.796% |
| Helix BioPharma Corp. | -14 Thousand CAD | -1399.364% |
| Microbix Biosystems Inc. | 7.48 Million CAD | 102.806% |
| Medicenna Therapeutics Corp. | -5000.00 CAD | -4098.22% |
| Satellos Bioscience Inc. | -8.81 Million CAD | 97.619% |
| Oncolytics Biotech Inc. | -403 Thousand CAD | 47.913% |
| Sernova Corp. | -445.55 Thousand CAD | 52.887% |